Market Overview

Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News

Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News
Related MRNS
Mid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis Therapeutics Shares Slide
28 Stocks Moving In Tuesday's Mid-Day Session
Vistagen - Nanocap CNS Drug Chasing Ketamine Fame (Seeking Alpha)
Benzinga's Top Upgrades, Downgrades For February 26, 2018
Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy
Biotechs Approaching New Waters (Seeking Alpha)

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits.

The stock moved mostly on sympathy for SAGE Therapeutics Inc (NASDAQ: SAGE), a biotech peer that released positive clinical data on its brexanolone treatment for major depressive disorder and subsequently surged 70 percent.

Street analysts expect the drug to advance to Phase 3 studies, eventually secure regulatory approval and potentially prove efficacious in treating Parkinson’s and essential tremor.

Sage’s progress was well interpreted by Marinus investors, who back a similar pipeline to treat postpartum depression and epilepsy. Marinus’ ganaxolone, a GABA modulator akin to SAGE-217, is in Phase 2 development for four separate trials.

At the time of publication, Marinus shares were set to open up 2.4 percent at $8.85, while Sage was up 1.7 percent at $158.99.

Related Links:

Hertz Moving In Sympathy With Avis Budget

5 Dry Bulk Shipping Stocks Moving In Sympathy With Diana Containerships Outsized Move

Hasbro, Mattel Just Proved That Sympathy Plays Don't Always Pay Off

Posted-In: ganaxolone SAGE-217Health Care Trading Ideas General Best of Benzinga


Related Articles (SAGE + MRNS)

View Comments and Join the Discussion!